# Research timeline and gaps: Injectable Peptide Stacks and Human Recovery

Selected publication milestones, not an exhaustive history or discovery priority claim.

**1991 — Local GH can change acute forearm protein kinetics; this establishes physiology, not lasting recovery.** [Original PMID2003602](https://pubmed.ncbi.nlm.nih.gov/2003602/).

**1992 — GH-plus-training trial in young men adds mass and whole-body synthesis without extra muscle-strength benefit.** [Original PMID1550219](https://pubmed.ncbi.nlm.nih.gov/1550219/).

**1994 — Long-term GH-deficiency replacement illustrates a separate baseline-deficiency indication.** [Original PMID8156094](https://pubmed.ncbi.nlm.nih.gov/8156094/).

**1995 — Older-adult matched-training comparison shows additional GH mass/water change without added strength.** [Original PMID7864103](https://pubmed.ncbi.nlm.nih.gov/7864103/).

**1997 — Older-adult GHRH before-after findings combine selected functional changes with null metabolic and composition measures; controls remain limited.** [Original PMID9005976](https://pubmed.ncbi.nlm.nih.gov/9005976/).

**1998 — Ipamorelin receptor profiling and animal hormone selectivity establish a mechanistic starting point.** [Original PMID9849822](https://pubmed.ncbi.nlm.nih.gov/9849822/).

**1999 — Human ipamorelin pharmacodynamics show GH stimulation without physical recovery endpoints.** [Original PMID10496658](https://pubmed.ncbi.nlm.nih.gov/10496658/).

**1999 — Two critically ill adult trials demonstrate high-dose GH mortality harm in a distinct severe clinical context.** [Original PMID10477776](https://pubmed.ncbi.nlm.nih.gov/10477776/).

**2001 — Mouse secretagogue adiposity effects challenge assuming all actions are explained by GH.** [Original PMID11162489](https://pubmed.ncbi.nlm.nih.gov/11162489/).

**2002 — Older-adult factorial GH/sex-steroid study shows sex- and endpoint-specific findings alongside adverse effects.** [Original PMID12425705](https://pubmed.ncbi.nlm.nih.gov/12425705/).

**2003 — Controlled perioperative GH produces selected walking and muscle-preservation benefit with frequent dose-related side effects.** [Original PMID12519419](https://pubmed.ncbi.nlm.nih.gov/12519419/).

**2006 — Blinded CJC-1295 ascending-dose human trials demonstrate prolonged GH/IGF-I activity.** [Original PMID16352683](https://pubmed.ncbi.nlm.nih.gov/16352683/).

**2006 — CJC pulsatility measurements refine endocrine engagement without adding a clinical recovery trial.** [Original PMID17018654](https://pubmed.ncbi.nlm.nih.gov/17018654/).

**2008 — MK-677 increases hormones and fat-free mass while measured function remains unchanged; glycemic monitoring supplies a safety boundary.** [Original PMID18981485](https://pubmed.ncbi.nlm.nih.gov/18981485/).

**2009 — A CJC cohort subset adds serum-proteomic markers, not independent functional replication.** [Original PMID19386527](https://pubmed.ncbi.nlm.nih.gov/19386527/).

**2009 — Capromorelin shows selected older-adult functional outcomes in a different drug and predefined limitation setting.** [Original PMID19174493](https://pubmed.ncbi.nlm.nih.gov/19174493/).

**2010 — A blinded athlete study retains a real sprint positive, with null other performance endpoints and loss after washout.** [Original PMID20439575](https://pubmed.ncbi.nlm.nih.gov/20439575/).

**2013 — GH rat tendon-bone repair is null in one protocol and mechanically worse in prolonged high-dose exposure.** [Original PMID23636184](https://pubmed.ncbi.nlm.nih.gov/23636184/).

**2014 — Human postoperative ipamorelin does not improve its key meal-tolerance endpoint despite rodent motility support.** [Original PMID25331030](https://pubmed.ncbi.nlm.nih.gov/25331030/).

**2014 Jul 23-30 — Tesamorelin improves adiposity endpoints in HIV-related disease with explicit metabolic monitoring.** [Original PMID25038357](https://pubmed.ncbi.nlm.nih.gov/25038357/).

**2016 — Two ROMANA trials show lean-mass gains without co-primary handgrip improvement in cancer cachexia.** [Original PMID26906526](https://pubmed.ncbi.nlm.nih.gov/26906526/).

**2026 — A recent BPC-157/TB-500 rat component comparison finds no added combination benefit, reinforcing molecule-specific testing.** [Original PMID42542926](https://pubmed.ncbi.nlm.nih.gov/42542926/).

## Research gaps

Direct human functional outcomes for the exact combination.

Formulation equivalence between long-acting albumin-binding CJC-1295 and products sold under similar names.

Component-dismantling evidence and patient-relevant synergy rather than hormone synergy.

Adequately powered functional endpoints and distinction between contractile tissue, fluid, appetite and measured recovery.

Longer-term controlled safety and net benefit under verified product exposure.

Translation of full-length thymosinbeta4 and newer TB-500 animal mechanical results to defined human indications without treating different peptides as one class.

## Boundary experiment

A preregistered blinded factorial comparison of formulation-verified CJC-1295, ipamorelin, their exact combination and placebo in a predefined adult recovery setting without diagnosed GH deficiency, with matched rehabilitation and an independently assessed functional recovery endpoint over4–24 weeks.